Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Updates In Management Of Pediatric Atopic Dermatitis
Description
The presentation provides an extensive overview of recent advancements in managing pediatric atopic dermatitis, highlighting several novel therapies. Key topics include updates on topical treatments such as phosphodiesterase inhibitors (e.g., crisabarol and rifumast), and the introduction of topical Janus kinase (JAK) inhibitors like ruxolitinib, which have shown effectiveness in reducing symptoms with minimal side effects. The discussion also covers the systemic therapies like dupilumab, which is now approved for children as young as six months, and newer IL-13 antagonist therapies, alongside JAK inhibitors such as abrocitinib and apatacitinib, both of which demonstrate promising efficacy but also come with potential side effects, particularly acne. The lecture emphasizes the importance of careful patient selection, ongoing education about treatments, and understanding the financial implications of accessing these therapies. The growing availability of non-steroidal options allows for better tailored management strategies in young patients suffering from atopic dermatitis, with a focus on balancing efficacy, safety, and cost. It concludes by acknowledging the need for more data on long-term safety and efficacy, particularly in younger children.
View moreConclusions
- Topical therapies, including crisaborole and roflumilast, show significant effectiveness in treating pediatric atopic dermatitis.
- Systemic therapies such as Janus kinase inhibitors (JAK inhibitors) and biologics are effective for moderate to severe cases of atopic dermatitis in children.
- Crisaborole and roflumilast can reduce flare-ups and improve overall skin condition in pediatric patients.
- Long-term use of crisaborole may maintain improvements in skin condition with fewer flares and less need for topical corticosteroids.
- Ruxolitinib has shown sustained itch control and significant improvement in skin lesions in adolescents and can be safely used with minimal side effects.
- Difamilast is effective for children with mild to moderate atopic dermatitis and has a favorable safety profile.
- Biologic therapies targeting IL-4/IL-13 pathways are now accessible for young patients and can effectively reduce symptoms of atopic dermatitis.
- New systemic therapies and topical medications offer diverse treatment options for managing pediatric atopic dermatitis, enhancing quality of life in affected children.
- Müller S, Maintz L, Bieber T. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. Allergy. 2024 Jun;79(6):1501-1515. doi: 10.1111/all.16009. Epub 2024 Jan 8. PMID: 38186219.
- You J, Li H, Wang Z, Zhao Y. Evaluating Efficacy and Safety of Crisaborole in Managing Childhood Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-Analysis. Br J Hosp Med (Lond). 2025 Jan 24;86(1):1-19. doi: 10.12968/hmed.2024.0575. Epub 2025 Jan 24. PMID: 39862023.
- Eichenfield LF, Gower RG, Xu J, Alam MS, Su JC, Myers DE, Sanders P, Vlahos B, Zang C, Lan J, Werth J. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged 2 to 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study. Am J Clin Dermatol. 2023 Jul;24(4):623-635. doi: 10.1007/s40257-023-00780-w. Epub 2023 May 15. PMID: 37184828; PMCID: PMC10184626.
- Yang H, Li P, Shu H, Qian H, Chen JP, Wang S, Miao LM, Li XL, Meng Y, Cao R, Luo XY, Ma L, Wang H. Efficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study. Paediatr Drugs. 2025 Jan 28. doi: 10.1007/s40272-025-00682-w. Epub ahead of print. PMID: 39873962.
- Simpson EL, Eichenfield LF, Alonso-Llamazares J, Draelos ZD, Ferris LK, Forman SB, Gooderham M, Gonzalez ME, Hebert AA, Kircik LH, Lomaga M, Moore A, Papp KA, Prajapati VH, Hanna D, Snyder S, Krupa D, Burnett P, Almaraz E, Higham RC, Chu DH, Berk DR. Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials. JAMA Dermatol. 2024 Nov 1;160(11):1161-1170. doi: 10.1001/jamadermatol.2024.3121. PMID: 39292443; PMCID: PMC11411450.
- Eichenfield LF, Serrao R, Prajapati VH, Browning JC, Swanson L, Funk T, Gonzalez ME, Hebert AA, Lee M, Boguniewicz M, Simpson EL, Seal MS, Krupa D, Hanna D, Snyder S, Chu DH, Almaraz E, Higham RC, Berk DR. Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial. Pediatr Dermatol. 2025 Feb 20. doi: 10.1111/pde.15840. Epub ahead of print. PMID: 39980188.
- Yong SB, Ting B, Malau IA, Wu SK, Huang XZ, Wang JY, Jingling L, Wei CC. Comparative efficacy of biologics and small molecule drugs in treating pediatric atopic dermatitis in patients aged 2-18 years: A 12-16 week network meta-analysis of randomized controlled trials. Pediatr Allergy Immunol. 2025 Feb;36(2):e70045. doi: 10.1111/pai.70045. PMID: 39936572.
- Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1797-1810.
- Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J Am Acad Dermatol. 2021 Jan;84(1):139-147. doi: 10.1016/j.jaad.2020.08.051. Epub 2020 Aug 18. PMID: 32822798.
- Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, Lansang P, Lynde CW, Papp KA, Prajapati VH, Turchin I, Yeung J. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol. 2023 Jan 25.